Schering Plough
Jun 30, 2008
Drug Makers Say FDA Safety Focus Is Slowing New-Medicine Pipeline
Nearly four years after Merck & Co. yanked the painkiller Vioxx off the market, beleaguered pharmaceutical-industry executives say they are facing a tough new regulatory climate that is altering the landscape ...
Comments
Showing posts
1 - 1 of 1
|
Joined: May 5, 2008
Comments: 17
|
Although affecting all therapeutic areas, I believe the recent increase in FDA scrutiny will have a particular effect on potential oncology treatments. The delay in approval for Provenge is a clear example of the FDA's difficulty in conducting a true cost/benefit analysis for potential products.
|
Judge it!
Showing posts
1 - 1 of 1
Please note by clicking on "Post Comment" you acknowledge that you have read the Terms of Service and the comment you are posting is in compliance with such terms. Be polite. Inappropriate posts may be removed by the moderator. Send us your feedback.
| Topic | Updated | Last By | Comments |
|---|---|---|---|
| Vytorin, Zetia risk assessed | Oct 7 | gdpawel | 3 |
| Some Doctors Leery Of Vytorin Following Key Study (from Apr '08) | Sep 15 | gdpawel | 4 |
| Study: No proof of Vytorin link to cancer | Sep '08 | gdpawel | 1 |
| Study: No proof Vytorin linked to cancer; other... | Sep '08 | OMGWTF | 2 |
| `Exercise in a pill' looms in the future | Aug '08 | Taylor | 1 |
| Vytorin | Jul '08 | Paulette Rogers | 3 |
| Doctors Urge Use Of Statins For Cholesterol -- ... (from Apr '08) | Jul '08 | Moy Paterson | 4 |
Aries
Most Popular